Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03224312 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chongqing Primary Aldosteronism Study

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv6
  2. Trial status: Active, Not Recruiting to Recruitingv5 Show 4 more changesShow less
    • Eligibility criteria shortened, about 7 words
    • Secondary endpoints: details revised at 7 of 7 entries
    • Study description shortened, about 159 words
    • Site details revised
  3. Re-verified, no change to tracked fieldsv4
  4. Enrollment target: 880 to 1500
    • Primary completion date: Dec 31, 2018 to Dec 31, 2027
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v3
  5. Primary endpoint revised
    • Secondary endpoints: 5 to 7
    • Study description expanded, about 195 words
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
We intends to conduct a series of original clinical research about PA, and establish a large cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular events, renal end points etc. We will establish a large sample of blood, urine, adrenal tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.
Trial Details
NCT Number NCT03224312
Lead Sponsor Chongqing Medical University
Conditions
(from sponsor)		 Primary Aldosteronism
Related terms Hyperaldosteronism
Enrollment 1,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov